Neuronetics(STIM)2025-03-04 12:00Revenue Performance - Preliminary unaudited fourth quarter revenue for 2024 was 74.5 million[3]. - Neuronetics' adjusted net pro forma revenue for FY 2024 was 145.0 million and 22 million in annualized cost synergies, with over 90% already implemented[7][9]. - Operating expenses for FY 2025 are projected to be between 98.0 million[13]. Strategic Initiatives - The acquisition of Greenbrook TMS was completed on December 9, 2024, enhancing the company's market position in mental health therapy delivery[11]. - The Better Me Provider program launched in July 2024, improving patient care with up to 3 times faster follow-ups and a 2.5x reduction in treatment initiation time[12]. Regulatory and Market Expansion - FDA clearance was received for NeuroStar Advanced Therapy as a first-line treatment for adolescents with major depressive disorder, expanding the total addressable market by approximately 35%[14]. Operational Milestones - Neuronetics achieved cash flow breakeven in the third quarter of 2025[10]. - The company shipped 50 systems in the fourth quarter of 2024[3].